cinacalcet pharmazac 30 mg
synthon hispania, s.l. - spania - cinacalcetum - compr. film. - 30mg - preparate antihormoni paratiroidieni medicamente antihormoni paratiroidieni
cinacalcet pharmazac 60 mg
synthon hispania, s.l. - spania - cinacalcetum - compr. film. - 60mg - preparate antihormoni paratiroidieni medicamente antihormoni paratiroidieni
cinacalcet pharmazac 90 mg
synthon hispania, s.l. - spania - cinacalcetum - compr. film. - 90mg - preparate antihormoni paratiroidieni medicamente antihormoni paratiroidieni
everolimus pharmazac 10 mg
synthon hispania s.l. - spania - everolimus - compr. - 10mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
everolimus pharmazac 2,5 mg
synthon hispania s.l. - spania - everolimus - compr. - 2,5mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
everolimus pharmazac 5 mg
synthon hispania s.l. - spania - everolimus - compr. - 5mg - inhibitori de protein-kinaza inhibitor selectiv al mtor
gefitinib alvogen 250 mg
pharmadox healthcare ltd. - malta - gefitinibum - compr. film. - 250mg - alte antineoplazice inhibitori de protein-kinaza
gefitinib labormed 250 mg
pharmadox healthcare ltd. - malta - gefitinibum - compr. film. - 250mg - inhibitori de protein-kinaza inhibitori ai tirozin kinazei (egfr)
zoledronic acid teva pharma
teva b.v. - acid zoledronic - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - medicamente pentru tratamentul bolilor osoase - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. tratamentul de boala paget osoase la adulți.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenți antineoplazici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.